GW Pharmaceuticals (NASDAQ:GWPH) is developing marijuana based medicine for epilepsy and following positive results in multiple epilepsy trials last year, the company’s shares have surged higher. With share prices near 52-week highs, and a market cap of more than $3 billion, investors are right to wonder if there’s more room left to climb.
